2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 253-262

  Ma, Ping ^a   Rahima Benhabbour, S ^a   Feng, Lan ^a   Mumper, Russell J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

2' Behenoyl paclitaxel; 4T1 mouse model; Metastatic breast cancer; Nanoparticle; Paclitaxel

Indexed keywords

2' BEHENOYLPACLITAXEL; LIPID NANOPARTICLE; NANOPARTICLE; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST METASTASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE MODELS, ANIMAL; FEMALE; LIPIDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; NEOPLASM METASTASIS; PACLITAXEL;

EID: 84878228297     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.009     Document Type: Article

References (33)

1. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
2. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37:1590-1598.
3. Gallo J.M., Li S., Guo P., Reed K., Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 2003, 63:5114-5117.
4. Lo J.-T., Chen B.-H., Lee T.-M., Han J., Li J.-L. Self-emulsifying o/w formulations of paclitaxel prepared from mixed nonionic surfactants. J. Pharm. Sci. 2010, 99:2320-2332.
5. Wang F., Zhang D., Zhang Q., Chen Y., Zheng D., Hao L., Duan C., Jia L., Liu G., Liu Y. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance. Biomaterials 2011, 32:9444-9456.
6. Yoshizawa Y., Kono Y., Ogawara K.-I., Kimura T., Higaki K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm. 2011, 412:132-141.
7. Lee M.-K., Lim S.-J., Kim C.-K. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007, 28:2137-2146.
8. Rose W.C., Clark J.L., Lee F.Y.F., Casazza A.M. Preclinical antitumor activity of water-soluble paclitaxel derivatives. Cancer Chemother. Pharmacol. 1997, 39:486-492.
9. Grover S., Rimoldi J.M., Molinero A.A., Chaudhary A.G., Kingston D.G.I., Hamel E. Differential effects of paclitaxel (Taxol) analogs modified at positions C-2, C-7, and C-3' on tubulin polymerization and polymer stabilization: identification of a hyperactive paclitaxel derivative. Biochemistry 1995, 34:3927-3934.
10. Feng X., Yuan Y.-J., Wu J.-C. Synthesis and evaluation of water-soluble paclitaxel prodrugs. Bioorg. Med. Chem. Lett. 2002, 12:3301-3303.
11. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
12. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Adams V.R., Mumper R.J. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur. J. Pharm. Biopharm. 2009, 72:9-17.
13. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., Mumper R.J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69:3918-3926.
14. Ryu B.-Y., Sohn J.-S., Hess M., Choi S.-K., Choi J.-K., Jo B.-W. Synthesis and anti-cancer efficacy of rapid hydrolysed water-soluble paclitaxel pro-drugs. J. Biomater. Sci. Polym. Ed. 2008, 19:311-324.
15. Dhanikula A.B., Panchagnula R. Preparation and characterization of water-soluble prodrug, liposomes and micelles of paclitaxel. Curr. Drug Deliv. 2005, 2:75-91.
16. Hayashi Y., Skwarczynski M., Hamada Y., Sohma Y., Kimura T., Kiso Y. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. J. Med. Chem. 2003, 46:3782-3784.
17. Lundberg B.B., Risovic V., Ramaswamy M., Wasan K.M. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J. Control. Release 2003, 86:93-100.
18. Ansell S.M., Johnstone S.A., Tardi P.G., Lo L., Xie S., Shu Y., Harasym T.O., Harasym N.L., Williams L., Bermudes D., Liboiron B.D., Saad W., Prud'homme R.K., Mayer L.D. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J. Med. Chem. 2008, 51:3288-3296.
19. Bradley M.O., Webb N.L., Anthony F.H., Devanesan P., Witman P.A., Hemamalini S., Chander M.C., Baker S.D., He L.F., Horwitz S.B., Swindell C.S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res. 2001, 7:3229-3238.
20. Stevens P.J., Sekido M., Lee R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res. 2004, 21:2153-2157.
21. Harries M., O'Donnell A., Scurr M., Reade S., Cole C., Judson I., Greystoke A., Twelves C., Kaye S. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Br. J. Cancer 2004, 91:1651-1655.
22. Bedikian A.Y., DeConti R.C., Conry R., Agarwala S., Papadopoulos N., Kim K.B., Ernstoff M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann. Oncol. 2011, 22:787-793.
23. Bradley M.O., Swindell C.S., Anthony F.H., Witman P.A., Devanesan P., Webb N.L., Baker S.D., Wolff A.C., Donehower R.C. Tumor targeting by conjugation of DHA to paclitaxel. J. Control. Release 2001, 74:233-236.
24. Kuznetsova L., Chen J., Sun L., Wu X.Y., Pepe A., Veith J.A., Pera P., Bernacki R.J., Ojima I. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg. Med. Chem. Lett. 2006, 16:974-977.
25. Shelanski M.L., Gaskin F., Cantor C.R. Microtubule assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci. 1973, 70:765-768.
26. Lee J.C., Timasheff S.N. In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry 1977, 16:1754-1764.
27. Ma P., Dong X., Swadley C.L., Gupte A., Leggas M., Ledebur H.C., Mumper R.J. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J. Biomed. Nanotechnol. 2009, 5:151-161.
28. Perkins W.R., Ahmad I., Li X.G., Hirsh D.J., Masters G.R., Fecko C.J., Lee J.K., Ali S., Nguyen J., Schupsky J., Herbert C., Janoff A.S., Mayhew E. Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int. J. Pharm. 2000, 200:27-39.
29. Ke X.Y., Zhao B.J., Zhao X., Wang Y., Huang Y., Chen X.M., Zhao B.X., Zhao S.S., Zhang X.A., Zhang Q.A. The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. Biomaterials 2010, 31:5855-5864.
30. Feng L., Wu H.L., Ma P., Mumper R.J., Benhabbour S.R. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo. Int. J. Nanomed. 2011, 6:2545-2556.
31. Kim J.-K., Howard M.D., Dziubla T.D., Rinehart J.J., Jay M., Lu X. Uniformity of drug payload and its effect on stability of solid lipid nanoparticles containing an ester prodrug. ACS Nano 2010, 5:209-216.
32. Dordunoo S.K., Burt H.M. Solubility and stability of Taxol: effects of buffers and cyclodextrins. Int. J. Pharm. 1996, 133:191-201.
33. Zhao L.H., Jin X.Q., Xu Y.H., Guo Y.X., Liang R., Guo Z.H., Chen T.F., Sun Y.H., Ding X.H. Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1. J. Exp. Clin. Cancer Res. 2010, 29:98-104.